

Replication assessment of *NUS1* variants in Parkinson's Disease

Bernabe I. Bustos*, Sara Bandres-Ciga, J. Raphael Gibbs, Dimitri Krainc, Niccolo E. Mencacci, Ziv Gan-Or and Steven J. Lubbe*, for the International Parkinson's Disease Genomics Consortium (IPDGC).

*Corresponding authors: Steven J. Lubbe, PhD (steven.lubbe@northwestern.edu) and Bernabe Bustos (bernabe.bustos@northwestern.edu)

Supplementary Information

Supplementary Table 1. Coverage analysis of NUS1 exons in IPDGC-WES and AMP-PD WGS data.

Assay	Cohort	SampleN	NUS1	Exon1	Exon2	Exon3	Exon4	Exon5
WES	IPDGC	1494	Depth	16	22	22	24	27
WES	IPDGC	1494	Variants	7	3	1	2	36
WGS	AMP-PD	2697	Depth	34	37	34	37	36
WGS	AMP-PD	2697	Variants	11	1	3	2	34

Supplementary Table 2. SKAT-O⁴ analysis of rare and infrequent coding variants in IPDGC-WES and AMP-PD WGS data.

IPDGC-
WES

AF	Gene	N_INFORMATIVE	NumVar	NumPolyVar	P-value
< 5%	NUS1	1494	6	6	0.891
< 1%	NUS1	1494	6	6	0.892

AMP-PD
WGS


AF	Gene	N_INFORMATIVE	NumVar	NumPolyVar	P-value
< 5%	NUS1	2697	5	5	0.640
< 1%	NUS1	2697	5	5	0.640

AF= Allele frequency. N_Informative= Number of informative samples. NumVar= number of tested available variants. NumPolyVar= number of polymorphic variants. SKAT-O test done in RVTEST⁵ (<http://zhanxw.github.io/rvtests/>).

Supplementary Table 3. Population frequency of *NUS1* variants assessed in Gao *et al.*, 2018⁶, in gnomAD v.2.11.

CHR	BP	REF	ALT	Total gnomAD	East Asian	South Asian	Non-Finish European	African	Latino
6	117996897	C	T	-	-	-	-	-	-
6	117996940	T	C	-	-	-	-	-	-
6	117996941	C	G	1.3x10-5 (2)	-	8.3x10-5 (2)	-	-	-
6	117997007	G	T	3.4x10-4 (55)	-	2.8x10-4 (6)	3.4x10-4 (21)	2.0x10-4 (3)	9.4x10-4 (23)
6	117997032	C	G	-	-	-	-	-	-
6	117997090	G	T	5.6x10-6 (1)	7.9x10-4 (1)	-	-	-	-
6	117997098	G	T	-	-	-	-	-	-
6	117997104	G	T	-	-	-	-	-	-
6	117997184	C	G	1.1x10-5 (2)	7.8x10-5 (1)	-	1.3x10-5 (1)	-	-
6	118014221	T	G	-	-	-	-	-	-
6	118014264	C	A	-	-	-	-	-	-
6	118014276	G	C	8.0x10-5 (2)	1.1x10-4 (2)	-	-	-	-
6	118015279	G	C	-	-	-	-	-	-
6	118024773	A	G	-	-	-	-	-	-
6	118024794	T	A	-	-	-	-	-	-
6	118024866	G	A	-	-	-	-	-	-
6	118028241	G	A	-	-	-	-	-	-
6	118028193	A	C	8.0x10-5 (2)	1.1x10-4 (2)	-	-	-	-

CHR=Chromosome. BP=Base pair. REF= Reference allele. ALT=Alternative allele. Frequency per total sample and population specific are shown. Allele counts for each frequency is represented in parentheses. Coordinates are in build hg19.



Supplementary Figure 1. Regional association plots for *NUS1* common variants. Logistic regression P-values for common variants in AMP-PD WGS dataset (upper panel, <https://amp-pd.org>), IPDGC-GWAS cohorts⁷ (middle panel) and PD GWAS Meta-analysis summary statistics without 23andMe individuals⁷ (lower panel). AMP-PD coordinates are in hg38 human genome build. IPDGC-GWAS and PD GWAS meta-analysis coordinates are in hg19 human genome build. Purple diamonds show the most significant SNP on each panel. Blue dots in the lower panel indicate low LD between variants ($r^2 < 0.2$).

Acknowledgments

We would like to thank all of the subjects who donated their time and biological samples to be part of this study. We would also like to thank all members of the International Parkinson's Disease Genomics Consortium (IPDGC). For a complete overview of members, acknowledgements and funding, please see <http://pdgenetics.org/partners>. We would like to thank the Accelerating Medicines Partnership initiative (AMP-PD) for the publicly available whole-genome sequencing data, including cohorts from the BioFIND study, the NINDS Parkinson's disease Biomarkers Program (PDBP), and MJFF Parkinson's Progression Marker Initiative (PPMI). As registered users of the AMP-PD, BIB, SJL, ZGO, JRG and SBC have access to individual-level data. This research was supported, in part, by the Intramural Research Program of the National Institutes of Health (National Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers 1ZIA-NS003154, Z01-AG000949-02, and Z01-ES101986.

Conflicts of Interest

D.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed. B.I.B, S.J.L and J.R.G. declare that they do not have conflict of interests.

Funding

D.K. is supported by the Simpson Querrey Center for Neurogenetics.

Code availability

<https://github.com/ipdgc/IPDGC-Trainees/blob/master/NUS1.md>

References

- 1 Jansen, I. E. *et al.* Establishing the role of rare coding variants in known Parkinson's disease risk loci. *Neurobiol Aging* **59**, 220 e211-220 e218, doi:10.1016/j.neurobiolaging.2017.07.009 (2017).
- 2 Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443, doi:10.1038/s41586-020-2308-7 (2020).
- 3 Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**, D886-D894, doi:10.1093/nar/gky1016 (2019).
- 4 Lee, S. *et al.* Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet* **91**, 224-237, doi:10.1016/j.ajhg.2012.06.007 (2012).
- 5 Zhan, X., Hu, Y., Li, B., Abecasis, G. R. & Liu, D. J. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423-1426, doi:10.1093/bioinformatics/btw079 (2016).
- 6 Guo, J. F. *et al.* Coding mutations in NUS1 contribute to Parkinson's disease. *Proc Natl Acad Sci U S A* **115**, 11567-11572, doi:10.1073/pnas.1809969115 (2018).
- 7 Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* **18**, 1091-1102, doi:10.1016/S1474-4422(19)30320-5 (2019).